Reviva Prices $10 Million Offering to Fund Schizophrenia Trial

Edgen Stock·Mar 19 2026, 03:32

Share to

Share to

Copy link

Key Takeaways

Reviva Pharmaceuticals announced a $10 million public offering priced at $1.50 per share to advance its clinical pipeline. The capital raise, aimed at institutional investors, introduces significant share dilution through the issuance of stock and a large number of warrants.

Public Offering: Reviva priced a public offering of 6,666,667 shares and accompanying warrants to raise approximately $10 million in gross proceeds.
Use of Funds: The net proceeds are primarily intended to fund the RECOVER-2 Phase 3 trial for its lead drug candidate, brilaroxazine, for schizophrenia.
Shareholder Dilution: The deal includes two series of warrants to purchase an additional 13.3 million shares, creating a potential overhang and diluting value for existing shareholders.

On March 18, 2026, Reviva Pharmaceuticals Holdings, Inc. priced a public offering to raise approximately $10 million in gross proceeds from healthcare-focused institutional investors. The company will sell 6,666,667 shares of its common stock at a combined price of $1.50 per share, which also includes accompanying warrants. The offering is expected to close on or about March 20, 2026, subject to customary closing conditions.

Offering Includes 13.3M Warrants, Signaling Future Dilution

The offering structure introduces significant potential dilution for current shareholders. Each share sold is bundled with two series of warrants, Series G and Series H, each allowing the holder to purchase an additional 6,666,667 shares. This represents a potential future influx of over 13.3 million shares. Both warrant series have an exercise price of $1.50 per share and are exercisable immediately. The Series G warrants expire in five years, while the Series H warrants have a shorter 12-month expiration.

Capital Earmarked for Phase 3 Schizophrenia Drug Trial

Reviva intends to use the net proceeds to advance its clinical pipeline, with a specific focus on its lead drug candidate, brilaroxazine. The capital will help fund the planned RECOVER-2 Phase 3 trial for brilaroxazine as a treatment for schizophrenia. Remaining funds will be allocated to working capital and general corporate purposes, positioning the company to pursue this key developmental milestone. A.G.P./Alliance Global Partners is serving as the sole placement agent for the transaction.

Reviva Prices $10M Public Offering at $1.50 Per Share

Offering Includes 13.3M Warrants, Signaling Future Dilution

Capital Earmarked for Phase 3 Schizophrenia Drug Trial